Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
posted on
Jan 26, 2023 11:32AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
I do not work in the biotech field, I am not a medical doctor or scientist.
When I read the definitions of these two cancers, "castration resistant" means hormone therapy is no longer effective while "hormone sensitive" means hormone therapy is effiective.
The Clinical trials specifiy this cancer type in the "conditions" section so I think they are different because they are targeting two different cancer conditions.
I'd like Bear to chime in here, I think this is a good 'Bear' question.